BaskhanBioPharma Inc

BaskhanBioPharma Inc maintains a strong liquidity position, with a current ratio of 6.87, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to KRW 3,535,412,920, and its free cash flow for the period is KRW 5,941,628,730, reflecting robust cash generation. The debt-to-equity ratio is 0.0, suggesting no long-term debt obligations, which further supports the company's liquidity profile. In terms of profitability, BaskhanBioPharma Inc demonstrates a return on equity (ROE) of 13.19% and a return on assets (ROA) of 11.63%. These figures are strong indicators of the company's efficiency in generating returns from its equity and total assets, respectively. The operating income of KRW 2,894,178,640 and net income of KRW 4,766,463,730 further underscore the company's profitability. The company's revenue is derived from a diverse range of products, including prescription drugs, general drugs, medical devices, cosmetics, and health functional foods. However, the input data does not provide specific revenue concentration by segment or geography, so it is not possible to determine if the company has significant exposure to any particular region or product line. BaskhanBioPharma Inc's growth trajectory is supported by its strong cash flow and profitability. The company's free cash flow of KRW 5,941,628,730 and operating cash flow of KRW 4,088,180,260 indicate a solid financial foundation for future growth. The capital expenditure of KRW -726,246,000 suggests that the company is not currently investing heavily in new capital projects, which may indicate a focus on maintaining existing operations rather than expansion. The risk assessment for BaskhanBioPharma Inc indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and the absence of long-term debt further reduces financial risk. The dilution potential is also low, with no significant dilution sources identified in the input data. There are no specific recent events or filings mentioned in the input data that would impact the company's operations or financial position. The company's financial statements and disclosures do not indicate any material changes or risks that would affect its current trajectory.